Novel biomarker technology for cancer diagnostics

Date:
July 15, 2020
Source:
Lund University
Summary:
A new way of identifying cancer biomarkers has been developed. The
new technology allows very sensitive, quick and cost-effective
identification of cancer biomarkers.



FULL STORY ==========================================================================
A new way of identifying cancer biomarkers has been developed by
researchers at Lund University in Sweden. The new technology allows
very sensitive, quick and cost-effective identification of cancer
biomarkers. The research is published in Nature Communication Biology.


========================================================================== Today, every third person will get cancer in their lifetime, and the
current trend suggests that in a few years that number will be one in
two. If diagnosed earlier than today, a majority of cancer cases would
have a much more favorable outcome for patients. WHO has projected that a
third of all cancers could be cured if diagnosed already at tumor stage
I/II, that is, asymptomatic patients.

CREATE Health Cancer Center at Lund university has in collaboration
with Immunovia AB developed a new technology combining the specificity
of antibodies with the sensitivity of next-generation sequencing. The technology will pave the way for the next generation of biomarker
discovery program in cancer, where there is still a tremendous unmet need.

"We have for years been developing advanced diagnostic approaches for multiplexed analysis of serum proteins, using a single drop of blood,
for the purpose of early diagnosis of complex disease, in particular
cancer. There is massive amount of information in blood and our
combination of proteomics and genomics will open up for rapidly
associating early tumor development with protein signatures. This
in turn will benefit the patients with a more favorable outcome and
overall survival. We are very excited with this novel next generation
of biomarker discovery tool," says Professor Carl Borrebaeck, director
of CREATE Health Cancer Center at Lund University.

About the method The novel approach, denoted ProMIS, Protein detection
using Multiplex Immunoassay in Solution, circumvents the inherent
technical problems in conventional biomarker research traditionally
utilizing biomatrices, e.g.

planar- or bead-based arrays, by instead profiling serum proteins in
solution .

Since the entire process can be performed in solution most inherent
problems traditionally present using solid support is avoided. ProMIS
utilizes scFv antibody fragments tagged with a DNA barcode. The
barcoded scFvs are mixed with biotinylated serum proteins coupled to streptavidin-coated magnetic beads, and bound antibodies are detected,
using next generation sequencing (NGS). The combination of proteomics (antibodies) and genomics (NGS) will uniquely result in both a multiplex
and ultra-sensitive read-out which in turn will increase the possibilities
and success rate to find tumors earlier. This will benefit both patient
and society.


========================================================================== Story Source: Materials provided by Lund_University. Note: Content may
be edited for style and length.


========================================================================== Journal Reference:
1. Mattias Brofelth, Anna Isinger Ekstrand, Shashank Gour, Ronnie
Jansson,
My Hedhammar, Bjo"rn Elleby, Anders Kvist, Christer Wingren,
Ulrika Axelsson, Carl A. K. Borrebaeck. Multiplex profiling of
serum proteins in solution using barcoded antibody fragments and
next generation sequencing. Communications Biology, 2020; 3 (1)
DOI: 10.1038/s42003-020- 1068-0 ==========================================================================

Link to news story: https://www.sciencedaily.com/releases/2020/07/200715123149.htm

--- up 1 hour, 54 minutes
* Origin: -=> Castle Rock BBS <=- Now Husky HPT Powered! (1337:3/111)